Biotech | May 09, 2022
SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
Tislelizumab is now approved for seven indications in China
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Subscribe To Our Newsletter & Stay Updated
